Last reviewed · How we verify
Myocardial Infarction Prevention
Approved treatments
- Aceon · Symplmed Pharms Llc
- Zontivity · Key Therap
- Lipitor · Pfizer Inc.
Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. - Zocor · Merck & Co.
- Micardis · Boehringer Ingelheim
Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. - Crestor · AstraZeneca
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor. - Lipitor · Pfizer
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis. - Altace · King Pfizer
Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure. - Norvasc · Pfizer Inc.
Long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing blood pressure and myocardial oxygen demand. - Mevacor · Merck & Co.
Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver. - Pritor · DongKoo Bio & Pharma
- Amlodipin · Boehringer Ingelheim
Clinical guidelines
- FDA label — 1L
To reduce the risk of myocardial infarction (MI) in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. - FDA label — 1L
To reduce the risk of myocardial infarction (MI) in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. - FDA label — 1L
To reduce the risk of myocardial infarction (MI) in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. - FDA label — 1L
To reduce the risk of myocardial infarction (MI) in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Myocardial Infarction Prevention patent landscape — cliff calendar, originator estates, attackable patents
- Myocardial Infarction Prevention treatment landscape brief
- Myocardial Infarction Prevention treatment updates RSS
Frequently asked questions about Myocardial Infarction Prevention
What drugs treat Myocardial Infarction Prevention?
Tracked treatments include Aceon, Zontivity, Lipitor, Zocor, Micardis, Crestor, Altace, Norvasc.
What is the treatment for Myocardial Infarction Prevention?
Standard treatment for Myocardial Infarction Prevention includes Aceon, Zontivity, Lipitor, Zocor, Micardis. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Myocardial Infarction Prevention?
FDA label publishes guidelines for Myocardial Infarction Prevention. 4 guideline references tracked.
Related
- Treatment landscape: Myocardial Infarction Prevention patent cliff · Myocardial Infarction Prevention CI report
- Treatment: Aceon · Symplmed Pharms Llc
- Treatment: Zontivity · Key Therap
- Treatment: Lipitor · Pfizer Inc.
- Treatment: Zocor · Merck & Co.
- Treatment: Micardis · Boehringer Ingelheim
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing